Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature

Published:2021-08 Issue:4 Volume:6 Page:100233
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Heregger R.,Huemer F.,Hutarew G.,Hecht S.,Cheveresan L.,Kotzot D.,Schamschula E.,Rinnerthaler G.,Melchardt T.,Weiss L.,Greil R.

Funder

Novartis

Eli Lilly and Company

Roche

Pfizer

Servier

Amgen

Paracelsus Medizinische Privatuniversität

Bristol-Myers Squibb

Merck

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference25 articles.

1. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades;Goffredo;J Surg Oncol,2013

2. Targeting VEGF-VEGFR pathway by sunitinib in peripheral primitive neuroectodermal tumor, paraganglioma and epithelioid hemangioendothelioma: three case reports;Prochilo;Case Rep Oncol,2013

3. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001);Druce;Horm Metab Res,2009

4. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas;Oh;Cancer,2012

5. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer;Peters;N Engl J Med,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antineoplastics;Reactions Weekly;2022-12-10

2. Hallmarks of Anaplastic Lymphoma Kinase Inhibitors with Its Quick Emergence of Drug Resistance;Pharmaceutical Fronts;2022-12

3. Targeted Therapies in Pheochromocytoma and Paraganglioma;The Journal of Clinical Endocrinology & Metabolism;2022-08-17

4. Mutational Profile and Potential Molecular Therapeutic Targets of Pheochromocytoma;Frontiers in Endocrinology;2022-07-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3